Cargando…

Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics

BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), the age-related expansion of mutant hematopoietic stem cells, confers risk for multiple diseases of aging including hematologic cancer and cardiovascular disease. Whole-exome or genome sequencing can detect CHIP, but due to those as...

Descripción completa

Detalles Bibliográficos
Autores principales: Uddin, Md Mesbah, Zhou, Ying, Bick, Alexander G., Burugula, Bala Bharathi, Jaiswal, Siddhartha, Desai, Pinkal, Honigberg, Michael C., Love, Shelly-Ann, Barac, Ana, Hayden, Kathleen M., Manson, JoAnn E., Whitsel, Eric A., Kooperberg, Charles, Natarajan, Pradeep, Reiner, Alexander P., Kitzman, Jacob O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128083/
https://www.ncbi.nlm.nih.gov/pubmed/35610705
http://dx.doi.org/10.1186/s12979-022-00278-9
Descripción
Sumario:BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), the age-related expansion of mutant hematopoietic stem cells, confers risk for multiple diseases of aging including hematologic cancer and cardiovascular disease. Whole-exome or genome sequencing can detect CHIP, but due to those assays’ high cost, most population studies have been cross-sectional, sequencing only a single timepoint per individual. RESULTS: We developed and validated a cost-effective single molecule molecular inversion probe sequencing (smMIPS) assay for detecting CHIP, targeting the 11 most frequently mutated genes in CHIP along with 4 recurrent mutational hotspots. We sequenced 548 multi-timepoint samples collected from 182 participants in the Women’s Health Initiative cohort, across a median span of 16 years. We detected 178 driver mutations reaching variant allele frequency ≥ 2% in at least one timepoint, many of which were detectable well below this threshold at earlier timepoints. The majority of clonal mutations (52.1%) expanded over time (with a median doubling period of 7.43 years), with the others remaining static or decreasing in size in the absence of any cytotoxic therapy. CONCLUSIONS: Targeted smMIPS sequencing can sensitively measure clonal dynamics in CHIP. Mutations that reached the conventional threshold for CHIP (2% frequency) tended to continue growing, indicating that after CHIP is acquired, it is generally not lost. The ability to cost-effectively profile CHIP longitudinally will enable future studies to investigate why some CHIP clones expand, and how their dynamics relate to health outcomes at a biobank scale. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12979-022-00278-9.